Voyager Therapeutics, Inc. VYGR 深 沪
等待开盘 11-10 09:30:00 美东时间
1.99
+0.125
+6.70%
华盛通- 最 高2.035
- 今 开1.89
- 成交量 181.06万股
- 最 低 1.825
- 昨 收 1.865
- 总市值 1.24亿
- 52周最高 5.478
- 市盈率 静 --
- 换手率 2.91%
- 52周最低 1.675
- 委 比 -13.19%
- 总股本 6222.92万
- 历史最高 31.91
- 量 比 1.77
- 振 幅 11.26%
- 历史最低 1.675
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Voyager Therapeutics 2026财年第3季度营收401.4万美元，同比下降69.97%
最新财报显示，Voyager Therapeutics 2026财年第3季度实现： 营业收入：401.4万美元 同比：下降69.97% 每股收益：-0.40美元...
11-07 08:00
Voyager Therapeutics收涨3.49%，成交额208.14万美元
11月3日，Voyager Therapeutics（VYGR）收涨3.49%，报1.78美元，成交额208.14万美元，市值1.1亿美元。 行情数据 • 开盘...
11-03 07:57
Voyager Therapeutics收跌6.45%，成交额184.6万美元
10月24日，Voyager Therapeutics（VYGR）收跌6.45%，报1.74美元，成交额184.6万美元，市值1.07亿美元。 行情数据 • 开...
10-24 07:03
Voyager Therapeutics advances leadership transition amid Alzheimer’s focus
An announcement from Voyager Therapeutics ( ($VYGR) ) is now available. On Octo...
10-21 20:28
Voyager Therapeutics Appoints Robin Swartz As President, Effective October 20, And Is Expected To Become CEO In Q1 2027
Swartz is expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer (CEO) in Q1 2027, following the receipt of initial acute safety data from a clinical trial of Voyager’s investigational tau silencing gene therapy VY1706 in adults with early Alzheimer’s disease (AD). Dr. ...
10-21 20:06
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
Voyager Therapeutics announced that Robin Swartz, its Chief Business and Operating Officer, has been appointed President and will succeed Alfred W. Sandrock Jr. as CEO in Q1 2027. Sandrock will remain CEO until the release of initial acute safety data for VY1706 in early Alzheimer’s disease, then continue on the Board. Swartz, with extensive experience in biotech, will lead Voyager’s pipeline advancement.
10-21 12:01
Voyager Therapeutics收跌7.77%，成交额112.44万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:01
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics announced its participation in several upcoming investor conferences in September 2026, including the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird’s Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. A webcast of the Wells Fargo fireside chat will be available on Voyager’s website and archived for 30 days. The company fo...
09-01 12:00
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
08-10 18:58
